VBL Therapeutics (VBLT) Misses Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
VBL Therapeutics Announces Third Quarter 2015 Financial Results and Provides Business Update
November 12, 2015 7:01 AM ESTInitiated GLOBE pivotal Phase 3 trial of VB-111 in recurrent glioblastoma (rGBM)
Reported positive, final Phase 2 data of VBL-111 in rGBM at the European Cancer Conference (ECC) 2015
Raised $15 million gross proceeds in an underwritten offering, expected to fund operations through readout of results from the pivotal GLOBE trial
TEL AVIV, Israel, Nov. 12, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of... More
